SCHEMBL3455935

SCHEMBL3455935

Nc1ncc(-c2ccn(CC(=O)Nc3ccccc3)c(=O)c2)c(-c2ccco2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 8/20 0.49
ADORA1 P30542 7/20 0.49
ADORA2B P29275 2/20 0.49
HDAC6 Q9UBN7 1/20 0.47
KDM4E B2RXH2 3/20 0.43
MEN1 O00255 3/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPT P10636 3/20 0.43
KMT2A Q03164 3/20 0.43
HPGD P15428 2/20 0.43
BLM P54132 2/20 0.43
MCL1 Q07820 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
PKM P14618 2/20 0.43
RECQL P46063 2/20 0.43
THRB P10828 1/20 0.43
ALOX12 P18054 1/20 0.43
NR4A1 P22736 1/20 0.43
BID P55957 1/20 0.43
BCL2A1 Q16548 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3455115 0.88 ADORA1 (0.55) ADORA2AADORA1ADORA2BHDAC6L3MBTL1
SCHEMBL13942443 0.85 ADORA2A (0.54) ADORA2AADORA1ADORA2BADORA3
SCHEMBL3455983 0.83 ADORA2A (0.54) ADORA2AADORA1ADORA2BKDM4EALDH1A1
SCHEMBL3455571 0.83 ADORA2A (0.56) ADORA2AADORA1ADORA2BKDM4EMEN1
SCHEMBL3456049 0.82 ADORA2A (0.55) ADORA2AADORA1ADORA2BADORA3HSD17B10
SCHEMBL3457651 0.81 ADORA2A (0.61) ADORA2AADORA1ADORA2BADORA3
SCHEMBL3455648 0.81 ADORA2A (0.54) ADORA2AADORA1ADORA2BADORA3
SCHEMBL3457967 0.81 ADORA2A (0.56) ADORA2AADORA1ADORA2BHDAC6ADORA3
SCHEMBL3455080 0.80 ADORA2A (0.61) ADORA2AADORA1ADORA2BADORA3
SCHEMBL3456132 0.80 ADORA2A (0.59) ADORA2AADORA1ADORA2BADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2246344-A1 Pyrimidine compounds and medicinal composition thereof Eisai R&D Management Co., Ltd. (JP) 2010-11-03 EP disclosed
CN-100519549-C Pyrimidine compounds and pharmaceutical compositions containing the same EISAI R&D MAN CO LTD (JP) 2009-07-29 CN disclosed
US-20090030023-A1 PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF HARADA HITOSHI 2009-01-29 US disclosed
US-20090030023-A1 PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF HARADA HITOSHI 2009-01-29 US disclosed
US-20090030023-A1 PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF HARADA HITOSHI 2009-01-29 US disclosed
US-7396836-B2 Pyrimidine compound and medicinal composition thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-07-08 US disclosed
US-7396836-B2 Pyrimidine compound and medicinal composition thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-07-08 US disclosed
US-7396836-B2 Pyrimidine compound and medicinal composition thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-07-08 US disclosed
CN-1575290-A Pyrimidine derivatives and pharmaceutical compositions containing that compounds EISAI CO LTD (JP) 2005-02-02 CN disclosed
US-20050004149-A1 Pyrimidine compound and medicinal composition thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-01-06 US disclosed
EP-1439175-A1 PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF Eisai Co., Ltd. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030023-A1 PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF CBR3, AHR, HCCS ADORA2A 539/4885ADORA1 328/4885ADORA2B 307/4885
US-20050004149-A1 Pyrimidine compound and medicinal composition thereof ADORA2B, ADORA2A, ADORA3 ADORA2A 2/4885ADORA1 4/4885ADORA2B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.